BMS-846372 is a potent and selective small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist primarily investigated for its therapeutic potential in the treatment of migraine. As a targeted… Read more
BMS-846372 is a potent and selective small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist primarily investigated for its therapeutic potential in the treatment of migraine. As a targeted agent, it functions by inhibiting the CGRP receptor, a key pathway implicated in the pathophysiology of migraine attacks. Within our catalogue, this category provides the essential compounds required for rigorous pharmaceutical research and development. Laboratories rely on these high-quality reference standards, including synthesized impurities, metabolic degradation products, and stable isotope-labelled standards, to support critical analytical workflows. These materials are indispensable for comprehensive impurity profiling, the validation of bioanalytical methods, and quality control processes, ensuring accurate characterization and quantification of the parent drug and its derivatives during preclinical and clinical development phases.